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Abstract 
Generation of the alternative pathway (AP) C3-convertase, the central amplification 
enzyme of the complement cascade, initiates by the binding of factor B (fB) to C3b to form 
the pro-convertase, C3bB. C3bB is subsequently cleaved by factor D (fD) at a single site in 
fB, producing Ba and Bb fragments. Ba dissociates from the complex, whilst Bb remains 
bound to C3b forming the active AP convertase, C3bBb. Using single-particle electron 
microscopy we have determined the 3D structures of the C3bB and the C3bBb complexes at 
~27Å resolution. The C3bB structure shows that fB undergoes a dramatic conformational 
change upon binding to C3b. However, the C3b-bound fB structure was easily interpreted 
after independently fitting the atomic structures of the isolated Bb and Ba fragments. 
Interestingly, the divalent cation-binding site in the von Willebrand type A domain in Bb 
faces the C345C domain of C3b whereas the serine-protease domain of Bb points outwards. 
The structure also shows that the Ba fragment interacts with C3b separately from Bb at the 
level of the α'NT and CUB domains. Within this conformation the long and flexible linker 
between Bb and Ba is likely exposed and accessible for cleavage by fD to form the active 
convertase, C3bBb. The architecture of the C3bB and C3bBb complexes reveals that C3b 
could promote cleavage and activation of fB by actively displacing the Ba domain from the 
vWA domain in free fB. These structures provide a structural basis to understand fundamental 
aspects of the activation and regulation of the AP C3-convertase. 
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Introduction 
Complement is a major component of innate immunity with crucial roles in microbial 
killing, apoptotic cell clearance and immune complex handling. Complement activation can 
be initiated by three different pathways: the classical pathway (CP), the alternative pathway 
(AP), or the lectin pathway (LP). Common to each initiation pathway is the formation of 
unstable bimolecular complexes, named C3-convertases (AP, C3bBb; CP/LP, C4b2a), which 
cleave C3 to generate C3b. The AP C3-convertase, C3bBb, is crucial within the complement 
cascade as it provides exponential amplification to the initial activating trigger.  C3b 
molecules generated by either the CP/LP or the AP C3-convertases bind fB, thus forming 
more AP C3-convertases and providing rapid amplification (1).  
To generate the AP C3-convertase, factor B (fB) first associates with C3b in a Mg2+-
dependent manner, to form the pro-convertase C3bB. In the presence of the serum protease 
factor D (fD), fB is cleaved and the N-terminal Ba fragment is released from the C3bB 
complex, creating the active AP C3-convertase (2).  
Interaction sites in both C3b and fB have been delineated using different approaches. 
The ??NT and C345C domains in C3b include putative binding sites for fB required for C3 
convertase formation (3-5). Both the ??NT and C345C domains are located in a part of the C3 
molecule that undergoes large rearrangements upon activation of C3 into C3b, which explains 
why C3 does not interact with factor B (6).  Similarly, structural analyses have suggested that 
formation of the AP C3-convertase probably depends on the structure and orientation of the 
CUB domain of C3b and that the interaction between C3b and fB is independent of the TED 
domain (7). 
Factor B is composed of five structural domains. Three short consensus repeats 
(SCRs) at the N-terminus comprise the Ba fragment, whereas the large Bb fragment at the C-
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terminus is comprised of a von Willebrand type A (vWA) domain followed by a serine-
protease (SP) domain. Mutagenesis analyses of fB and functional characterization of rare 
mutations and common polymorphims associated with diseases involving complement 
dysregulation have suggested regions in the fB molecule that are crucial for the interaction 
with C3b (8-11). Thus, a number of fB residues near the Mg2+-dependent metal ion-dependent 
adhesion site (MIDAS), including D279 (all amino acids are numbered to include the 25 aa-
long signal peptide), in the vWA domain have been shown to influence the initial recognition 
of C3b by fB and the stability of the AP C3-convertase C3bBb (8-11). Mutagenesis studies 
have shown that the fB vWA α1 helix also contributes to the C3b-binding region of the fB 
vWA domain, whilst the fB vWA α4/5 helix region is somewhat removed from the C3b-
binding region and more likely is involved in the binding site recognized by the complement 
regulators DAF and CR1 in C3bBb (12).  
 Formation of the C3bB complex also involves contact with the Ba domain (13). Using 
mutagenesis, antibody blocking and surface plasmon resonance methods it has been shown 
that both the triad of SCR domains (14-16) and an 8-aa long unstructured fragment at the 
amino terminus of the Ba fragment (17) provide important binding sites for C3b.  
The crystal structure of human fB, recently resolved at 2.3Å resolution, demonstrated 
that the Ba domain was not extended but folded back onto the Bb domain.  SCR2 and SCR3 
of Ba were packed tightly into an antiparallel dimer capped by SCR1 (6). These structural 
data also indicate that SCR1 probably hinders access of the ligand C3b to the MIDAS of the 
vWA domain and that the triad of SCR domains is probably only weakly associated with the 
vWA and SP domains. Most interestingly, comparison of the factor B pro-enzyme (18) and 
the Bb fragment (19) structures, suggests that fB undergoes conformational changes upon 
binding to C3b, displacing the helix αL from its binding groove in the vWA domain and 
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exposing the long linker domain between the SCR3 and the vWA domains of fB that contains 
the scissile bond cleaved by fD (7, 18, 19). 
Here, we sought to elucidate the structure of AP pro-convertase C3bB. To this end we 
have generated stable C3bB complexes in the presence of Ni2+, purified them and determined 
their 3D structure at ~27 Å resolution using electron microscopy (EM). We also report 
structural analysis of the AP convertase C3bBb using the fB mutant D279G. These studies 
have revealed the architecture of the C3bB and C3bBb complexes providing key insights into 
the initial stages of the AP C3-convertase formation, its activation by fD, and fundamental 
aspects of its regulation. 
Results and Discussion 
Electron microscopy of C3b and C3bB(Ni2+) complexes reveals that fB binds near the 
C345C domain in C3b. 
The Ni2+ cation was used instead of Mg2+ to promote a stable C3bB(Ni2+) complex 
that is otherwise undistinguishable from the physiological C3bB(Mg2+) pro-convertase (8, 20, 
21). Briefly, purified C3b and fB were mixed at 1:2 molar excess of fB in the presence of 5 
mM NiCl2. Subsequently, the C3bB(Ni2+) complex was purified by gel filtration 
chromatography (SI Fig. S1; SI Materials and Methods) and fresh fractions containing 
C3bB(Ni2+) were applied to carbon-coated EM grids and observed by electron microscopy 
(EM) after staining.  Images from individual molecules were clearly detected in the EM fields 
(SI Fig. S2),these were extracted and reference-free 2D averages were obtained using EMAN 
(22) and maximum likelihood analysis (23). Averages of C3b were clearly evocative of the 
typical structure of C3b (Fig. 1A), whereas those of the complex were clearly larger, 
indicating the presence of an additional component bound to C3b (Fig. 1B). C3bB(Ni2+)
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averages revealed views of the complex with an abundance of distinct shapes (Fig. 1B), 
indicating that it has likely bound to the support film in many different orientations 
representing rotations along its longitudinal axis. This assumption was confirmed later when 
performing the 3D reconstruction of the complex (see below). By contrast, single C3b 
molecule averages complied with a predominant orientation, probably due to the ‘flat’ nature 
of its structure (24, 25).  
Images from single C3b molecules and the C3bB(Ni2+) complex were processed using 
angular refinement methods to reconstruct their 3D structures. For each sample, we performed 
two independent experiments using as initial template for refinement either a very low 
resolution (> 60 Å) density map obtained after filtering the atomic structure of C3b, or a 
featureless Gaussian blob after adding noise. In both refinements, identical 3D solutions were 
obtained, compatible with the reference-free averages, indicating the absence of a significant 
bias from the initial reference (SI Fig. S3). During refinement, we detected that the data set 
for the C3bB(Ni2+) complex covered views of the complex in many different orientations, 
whereas a more limited range of views was obtained for the free C3b molecule. Therefore, we 
collected additional data for C3b after tilting the specimen holder to complete the range of 
views (see Methods for details). 
The 3D structure of C3b obtained by EM at a resolution of ~27 Å is,  within the limits 
of this resolution, virtually identical to the published crystal structures (24, 25) (Fig. 1C). 
These atomic coordinates can be unambiguously fitted using unbiased computational methods 
into our EM density, allowing a straightforward assignment of the different domains of the 
EM structure to specific domains of C3b. On the other hand, the C3bB(Ni2+) complex at a 
similar resolution reveals significant additional mass located in the proximities of the C345C 
domain but contacting a broad area of C3b (Fig. 1D and 2A). The atomic structure of C3b 
was resolved within the EM structure of the C3bB(Ni2+) complex by an exhaustive 6-
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dimensional search looking for all its possible orientations with the EM map. C3b was readily 
located within the complex given its very characteristic shape (Fig. 1D). 
Overall, these findings indicate that the C3bB(Ni2+) complex presents a more globular 
shape than the single C3b molecule, which allows the complex to adopt different poses on the 
carbon-coated support film. Furthermore, the comparison between the 2D averages and the 
3D structures of C3b and C3bB(Ni2+) revealed that the two data sets were clearly distinct 
(Fig. 1A and 1B), confirming the homogeneity of both preparations and pinpointing the 
location of fB in the C3bB(Ni2+) complex. 
Open conformation of fB within the C3bB(Ni2+) complex 
We comprehensively analyzed the conformation of fB after binding to C3b. The 
density of the fitted C3b was subtracted from that of the C3bB(Ni2+) complex to determine the 
region of the map that accounts for fB (Fig. 2A and 2B). fB in complex with C3b revealed a 
well defined V-shape density divided into a large and a small domain, notably distinct from 
the compact globular shape that represents the crystallized isolated fB when observed at a 
similar resolution (Fig. 2B). Such differences indicate that fB undergoes substantial 
conformational changes when binding to C3b, as previously suggested (18). 
To analyze further the conformation of fB within the C3bB(Ni2+) complex we 
performed several fitting experiments within the density assigned to fB. Since the crystal 
structure of full-length factor B, recently solved at 2.3Å resolution (PDB file 2OK5), could 
not account for the observed density, we divided the fB structure into two halves, one 
containing the three SCRs (amino acid 26 to 220) and the other including the vWA and the SP 
domains (amino acid 253 to 764). The linker between SCR3 and vWA, including the αL
helix, was removed from the analysis since its conformation in our structure should be 
considerably different to that in the lock conformation of factor B, and we cannot model these 
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changes at the resolution of our EM maps. When the atomic structure of the vWA-SP half 
was resolved within the whole density of fB in the C3bB(Ni2+) complex using computational 
methods, vWA-SP was unambiguously located at the larger EM domain (cross-correlation 
coefficient 0.76) (Fig. 2C) . In fact, this is the only region of the EM map with sufficient size 
to accommodate Bb and, as a consequence, the remaining small domain of the fB EM density 
must comprise the Ba fragment containing the N-terminal SCR1-3 domains (Fig. 2C). Given 
the flat shape of the vWA-SP region in the C3bB(Ni2+) complex, these two domains were 
found to fit the EM structure in only two possible orientations, placing the SP and vWA 
domains at either end of the large EM domain respectively (SI Fig. S4). One of these two 
solutions was discarded since it placed the SCR1-3 domains in a location where connection to 
the vWA domain could not be achieved with the length of the linker between them. The 
atomic structure corresponding to this region of fB (Ba fragment) could only be fitted 
manually, placing its C-terminus in the proximity of the vWA N-terminus, to best 
accommodate to the EM density (Fig. 2C). Therefore, the proposed orientation of the SCR1-3 
triad represents an informed approximation. 
Mechanistic insights into the assembly of the C3bB pro-convertase 
The proposed arrangement for the C3bB(Ni2+) complex illustrates key events during 
formation of the C3bB pro-enzyme. Firstly, consistent with early biochemical data (13), it 
shows that the Ba and Bb fragments both interact with C3b (Fig. 2 and 3). Moreover, it 
reveals that the vWA domain interacts with C345C with the MIDAS facing towards C3b (Fig. 
3A), which is also in agreement with previous data demonstrating that a number of fB 
residues near the MIDAS influence the initial recognition of C3b by fB and the stability of the 
AP C3-convertase (8-11). The putative C3b-interacting sites in the vWA are also located as 
expected within the C3bB structure. Thus, the fB vWA α1 helix, shown by mutagenesis to 
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contribute to the C3b-binding region of the fB vWA domain (12), faces the interface with 
C3b, whereas the vWA α4/5 helix, not implicated in the interaction and more likely involved 
in the binding site recognized by the complement regulators DAF and CR1, faces away from 
the complex (Fig. 3A). 
Most important is the distortion in conformation of fB bound to C3b in the C3bB(Ni2+)
complex compared to that recently reported for isolated fB (18). In the C3b-bound fB, the 
vWA-SP tandem is maintained as a unit, whereas the SCR1-3 region is displaced, likely 
interacting with the α'NT and CUB domains of C3b (Fig. 3B). This C3b-bound fB 
conformation supports the proposed model for the activation of fB, which suggests that upon 
binding to C3b the three SCRs of fB dislocate from the vWA and SP domains to allow access 
of the vWA domain to C3b (7, 18). The data also demonstrate contact points between the N-
terminal region of Ba and the α'NT domain of C3b and between the Ba SCR2/3 and the CUB 
domain, in agreement with early mutagenesis, antibody blocking and surface plasmon 
resonance experiments (14-17). 
The proposed C3bB structure validates the hypothesis that the large conformational 
rearrangements of fB upon interaction with C3b expose the flexible linker between the vWA 
and SCR3 domains that contains the site cleaved by factor D. This conformational change 
implies a major displacement of the SCR1-3 triad. Such a movement is certainly possible 
given the long and flexible linker (residues 221-252) connecting SCR3 with the vWA domain, 
only some of which is evident in the electron density of the published atomic structure of 
factor B (18). This linker must be cleaved between residues 259 and 260 by factor D to 
release the Ba fragment (26-259) in order to form the active convertase. Our model would 
place this cleavage point in the region connecting the two sides of the open conformation of 
fB in the C3bB complex. It is, therefore, quite exposed and potentially accessible to factor D. 
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It has been hypothesized that dislocation of the SCRs from the vWA and SP domains 
may be coupled, through the short SCR3-αL connecting loop, to the displacement of helix αL
from its binding groove in the vWA domain. This, in turn, may induce the vWA and SP 
domains to adopt a conformation more closely resembling that of the active Bb fragment (18). 
Therefore, we tested whether the atomic structure of the active Bb fragment, where the vWA 
domain is rotated with respect to the SP domain (18), fitted better into the fB EM density in 
our structure of the C3bB complex. However, whilst the atomic structure of the activated Bb 
fragment also adequately fitted the EM structure, the differences in cross-correlation 
coefficients between the two “Bb” fits were not sufficient to allow a computational 
discrimination between the models (data not shown).
3D structure of the active C3bBb complex 
In order to support our model for the C3bB(Ni2+) complex, we generated a stable 
active C3bBb convertase. We used in this case the fB-D279G mutant because Ni2+ does not 
stabilizes the active enzyme to the same extent as the pro-enzyme. The fB-D279G mutant 
promotes high-affinity C3b-binding and it is correctly cleaved by factor D in the C3bB 
proenzyme to generate a very stable, functionally-active, AP convertase C3bBb (8, 11, 12) (SI
Materials and Methods). The C3bBb279G complex was purified by gel filtration (SI Fig. S5) 
and analyzed by EM in a similar way to the C3bB(Ni2+) complex. Intriguingly, some 2D 
averages of C3bBb revealed lobes of density projecting out from the C3b structure; we later 
ascribed these to the C345C, vWA and SP domains (Fig. 4A). Some of these 2D averages are 
very similar to the EM images of a AP convertase generated with fB-WT reported earlier by 
Smith et al. (26) suggesting that the SP domain projects out from the convertase. 
3D reconstruction analyses showed that the active convertase lacked the small domain 
of fB in the C3bB complex that we had ascribed to the Ba fragment (Fig. 4B), fully 
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supporting our structural model. Interestingly, during the 3D refinement we observed that the 
density accounting for the SP domain was spread out along a range of possible conformations, 
reducing its average density in the 3D reconstruction (Fig. 4B). Reference-free 2D averages of 
the EM data revealed that whereas some averages shown a defined three-dot pattern (Fig. 4C, 
i), most side views of C3bBb demonstrated a well defined C3b molecule with an indistinct 
density for the projecting Bb region (Fig. 4C, ii). Such blurring suggests that the conformation 
of the vWA-SP domains is flexible, likely due to the absence of additional interaction points 
provided by the Ba SCR triad. In addition, the C3bBb structure shows that the SP domain of 
fB projects from the structure without contacting C3b and makes the catalytic site accessible 
to its substrate. Whether this difference between C3bB and C3bBb regarding the position of 
the SP domain is a consequence of conformational changes within the Bb fragment after the 
release of the Ba fragment cannot be solved at the resolution provide by our studies.
Functional implications of the 3D structures of C3bB(Ni2+) and C3bBb regarding decay 
acceleration mediated by DAF, CR1 and fH. 
The AP C3 convertase plays a central role in the amplification of complement cascade 
and for this reason its activity is strictly regulated. This regulation is achieved by modulating 
the stability of the AP C3–convertase, which localize complement amplification to the surface 
of the pathogens and prevents unspecific damage to self-tissues. Complement regulatory 
proteins either stabilize the C3bBb complex (Properdin) or accelerate its decay (factor H (fH), 
decay accelerating factor (DAF) or complement receptor 1 (CR1)). The C3bB and C3bBb EM 
structures described here shed new light on the mechanisms underlying the decay acceleration 
mediated by DAF, CR1 and fH. 
In DAF, the functional activity is located within four SCR domains at the N-terminus. 
Using surface plasmon resonance it has been shown that DAF mediates decay of the C3bBb 
convertase, but not of the proenzyme, C3bB, and the major site of interaction is within the Bb 
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fragment (27). Using truncated recombinant DAF molecules it has been demonstrated that 
DAF-SCR2 interacts with Bb, whereas DAF-SCR4 interacts with C3b. These data suggest 
that DAF interacts with C3bBb through major sites in SCR2 and SCR4. It has been suggested 
that the high affinity of binding to Bb via SCR2 (compared to little or no binding to fB), 
concentrates DAF on the active convertase, whereas the weaker interactions through SCR4 
with C3b directly mediate decay acceleration (28). 
We have already discussed that the fB vWA α4/5 helix region is exposed in our 
structure (Fig. 3) and that mutagenesis data highlight this helix region as a binding site 
recognized by DAF and CR1 (12). We recently described a novel fB mutation, K323E, in a 
patient with atypical hemolytic uremic syndrome (aHUS) that makes the C3bBb convertase 
resistant to decay by DAF and fH (11). This mutation, located in close proximity to the α4/5 
helix region of the vWA domain (Fig. 3), is remarkable because it neither modifies the 
formation rate of the C3bB and C3bBb complexes, nor their spontaneous decay, suggesting 
that the mutation specifically affects the binding site in the vWA domain for the complement 
regulators DAF and fH (11).
The C3bB and C3bBb EM structures described here support the concept of two 
binding sites for DAF in the C3bBb complex, one located on the surface of the vWA domain 
in Bb, away from the interaction surface with C3b (DAF-SCR2), and the other in C3b in the 
region that is occupied by the Ba fragment in the C3bB pro-convertase (DAF-SCR4). This 
readily explains the requirement for Ba removal from the C3bB complex in order that DAF 
can bind and mediate efficient decay acceleration.
Concluding remarks 
The alternative pathway (AP) C3-convertase is an unstable bimolecular complex 
formed by C3b and factor B that plays a crucial role within the complement cascade as it 
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provides the exponential amplification to the initial activating trigger. Assembly and 
regulation of the AP C3 convertase is exquisitely modulated to make possible the elimination 
of foreign agents by effector cells while at the same time protecting self-tissues from 
complement-mediated destruction. In fact, alterations in its formation rate, its stability or its 
regulation result in AP complement dysregulation leading to infectious diseases or tissue 
damage (29). Understanding how the AP convertase is assembled and regulated is, therefore, 
essential. Here we present in 3D the conformational transitions of fB following binding to 
C3b and formation of the AP pro-enzyme. Importantly, we demonstrate that binding to C3b 
promotes an opening of the fB conformation by displacing the SCR1-3 region (Ba fragment) 
from the SP-vWA tandem (Bb fragment). This open conformation of fB exposes the linker 
connecting the Bb and Ba fragments, permitting its cleavage by fD. Interestingly, the 
conformation of Bb in the active convertase reveals some degree of flexibility, with the SP 
domain adopting various conformations with respect to C3b. Our model also reveals 
important aspects of the regulation of the AP C3 convertase by DAF and perhaps other 
complement regulators like fH and CR1. These data will aid to explore the potential of the AP 
C3 convertase as a therapeutic target in the development of inhibitors to prevent or reduce 
tissue damage caused by dysregulated complement activation. Most importantly, our model 
provides a structural framework onto which other proteins of considerable interest in the 
pathophysiology of the AP convertase, like properdin or C3Nef, can be easily modelled. The 
methodology used in this work, single particle electron microscopy, in combination with 
crystallography offers a powerful tool to dissect protein interactions underlying the activity 
and regulation of this remarkable protein complex, the AP C3 convertase. 
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Materials and Methods
Electron microscopy and 3D reconstruction 
Purified C3b, C3bB(Ni2+) or C3bBb complexes in 25mM TrisHCl pH8.0, 50mM NaCl 
were applied to carbon-coated grids and negatively stained with 1% uranyl formate. The 
molecular weight of these complexes (~200kDa) did not allow their detection without 
staining. Observations were performed in a JEOL 1230 electron microscope operated at 
100kV and micrographs were recorded at a nominal magnification of 50,000 under low dose 
conditions. Micrographs were digitized and averaged to 4.2 Å/pixel and the contrast transfer 
function estimated using CTFFIND3 (30) and corrected by flipping phases. Around 6000 
images of molecules for each specimen were extracted and refined using EMAN (22). 
Reference-free averages were obtained using EMAN and maximum likelihood (23). We used 
two different starting 3D templates for refinement in two independent experiments. Identical 
results were obtained with either initial reference (SI Fig. S3), substantiating the final 
reconstruction and the absence of bias during the refinement. One reference was built by low-
pass filtering the atomic structure of C3b (PDB file 2i07) to very low resolution (> 60 Å) 
whereas a second template was a featureless noisy Gaussian blob (SI Fig. S3). Images 
collected for the C3bB(Ni2+) and C3bBb complexes revealed adequate Euler angles coverage. 
On the other hand, images of C3b mostly corresponded to tilting angles around an abundant 
front view, consistent with the flat appearance of C3b. In order to increase this angular 
coverage, micrographs were also taken after tilting the specimen holder at 20 and 35 degrees, 
and the images were added to the data set collected without tilting. The resolution of the maps 
was estimated to be ~28 Å, ~27 Å and ~28 Å for C3b, C3bB(Ni2+) and C3bBb respectively by 
Fourier Shell Correlation using the criteria of a correlation coefficient of 0.5. The absolute 
handedness of the reconstruction was defined by comparison with the atomic structure of 
C3b.
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Fitting of the atomic structures into the EM maps 
We performed a rigid-body fit of C3b (PDB file 2i07) into the EM reconstruction of 
C3b and the C3bB(Ni2+) complex using ADP_EM (31). C3b was unambiguously located in 
the C3bB(Ni2+) complex and a difference map between this fitted C3b and the full map was 
used to extract the density in the complex assigned to fB. The VWA and SP domains of fB 
(PDB file 2OK5) (18) were fitted as a rigid-body into this difference map using ADP_EM 
without any a priori assumption. Only one solution was compatible with the polypeptide 
backbone linking SCR3 to the vWA domain, this solution was then selected. The Ba fragment 
corresponding to the SCR1-3 trimer was manually fitted in the remaining density. 
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Figure Legends 
Figure 1. Electron microscopy and 3D reconstruction of C3b and C3bB(Ni2+)
(A) Reference-free 2D averages obtained for the data set containing images of single 
molecules of C3b. These averages reveal a characteristic “L” shape evocative of the C3b 
crystal structure. (B) Reference-free 2D averages of C3bB(Ni2+) display a bulky appearance 
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compatible with fB binding to C3b. (C) Front view of the 3D structure of C3b derived from 
the EM data at a resolution of 28 Å (gray density). The atomic structure of C3b (PDB file 
2i07) has been fitted within the EM map and displayed in purple with the C345C and CUB 
domains highlighted in orange and blue respectively. (D) Several views of the 3D structure of 
C3bB(Ni2+) at 27 Å resolution (gray density). Fitting of the atomic structure of C3b (PDB file 
2i07) allows the assignment of specific regions of the EM map to specific C3b domains. 
Some densities of the 3D reconstruction cannot be accounted by C3b (labeled as asterisks), 
and correspond to C3b-bound fB.  
Figure 2. Open conformation of fB within the C3bB(Ni2+) complex
(A) Views of the 3D reconstruction of C3bB(Ni2+). C3b in the complex has been colored in 
orange whereas fB is shown in green. (B) The structure of inactive fB (PDB file 2OK5) 
shows a compact conformation (left panels). This structure was filtered to ~25 Å resolution 
and was compared with the EM reconstruction (top left panel). C3b-bound fB was extracted 
by calculating the difference map between the EM density for C3bB(Ni2+) and the fitted 
atomic structure of C3b (right panel), and was found to display a more open conformation. 
SP, vWA and SCR1-3 domains have been colored in pale blue, green and yellow respectively. 
(C) Fitting of the atomic structure of fB into the structure of C3bB(Ni2+) complex. fB 
structure was divided in two segments corresponding to Bb and Ba fragments, and fitted 
separately within the density assigned to fB in the complex.  
Figure 3. Structural insights in the assembling of the pro-convertase
(A) Representation of an atomic model for fB within the C3bB(Ni2+) complex. For clarity 
only the C345C domain of C3b is represented. Color codes for domains as in Fig. 2. Specific 
residues have been highlighted representing them as space-filled amino acids.  These include 
D279 (known to affect pro-enzyme formation), K323 (known to affect regulation by DAF) 
and Q34 (to label the N-terminus of the Ba fragment). The vWA α1 helix (contributing to the 
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C3b-binding region) and vWA α4/5 helix (implicated in the DAF/CR1 binding site) are 
highlighted in blue and red ribbons, respectively. The N-terminus of the C3b α’ chain (α’NT) 
is depicted with space-filled amino acids. (B) A side view of the structural model of the 
C3bB(Ni2+) complex where the atomic structure of C3b (PDB file 2i07) is also represented in 
purple color. Color codes as in Fig. 1 and 2. 
Figure 4. 3D structure of the C3bBb convertase 
(A) A reference-free 2D average corresponding to a side view of the C3bBb complex where 
the vWA and SP domains appear projecting from the C3b structure. (B) Two views of the 
C3bBb complex revealing that the density assigned to the SCR1-3 domains in the structure of 
C3bB(Ni2+) is missing. This reconstruction represents a 3D average where the density of the 
SP domain is blurred due to conformational flexibility. (C) The flexibility of the vWA-SP 
cassette projecting from the C3bBb complex is reflected in the 2D reference-free averages of 
the data. Whereas some averages show a good definition of 3 dots of density corresponding to 
the C345C, vWA and SP domains (i), others reveal some blurring of this area (ii) whist 
maintaining the definition of the C3b molecule. 
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Supplementary Materials and Methods 
Preparation of the complement C3b fragment. 
C3 was prepared from pooled normal human plasma.  Plasma was subjected to a 4-
12% cut with PEG4000, the pellet was solubilized in 10mM Na/K phosphate pH7.6, 5mM 
NaCl and applied to a DEAE-Sepharose anion exchange column attached to an Akta Prime 
system (GE Healthcare, Amersham, UK).  Protein was fractionated using a gradient to 0.5M 
NaCl, C3-containing fractions were identified by SDS-PAGE, dialyzed against 20mM Na/K 
phosphate pH6, 60mM NaCl and applied to a Source S cation exchange column (GE 
Healthcare).  Protein was eluted with a gradient to 0.5M NaCl. C3-containing fractions were 
pooled and concentrated. C3b was generated by limited digestion with trypsin as previously 
described (Sánchez-Corral P, et al. (1989) Separation of active and inactive forms of the third 
component of human complement, C3, by fast protein liquid chromatography (FPLC). J 
Immunol Methods 122(1):105-113.) and re-purified by gel filtration on a SuperoseTM 6 
10/300 column (GE Healthcare). C3b was obtained without any detectable contaminants or 
aggregates (Supplementary Figure 1A). 
Production and purification of recombinant fB 
The D279G amino acid substitution was introduced in the fB cDNA by using 
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and appropriate 
primers. Both cDNAs encoding full length fB-WT and fB-D279G were introduced in the 
eukaryote expression vector pCI-Neo (Promega, Madison, WI) and the resulting clones 
entirely sequenced to confirm a correct DNA sequence. CHO cells were maintained in Ham-
F12 medium (GIBCO-BRL, Carlsbad, CA) supplemented with 10% fetal calf serum, L-
glutamine (2 mM final concentration), penicillin and streptomycin (10 U/ml and 100 μg/ml).  
The neomycin analogue, G418 sulfate (Geneticin; GIBCO-BRL, Carlsbad, CA), at 500 
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μg/mL, was used for selection of transfected cells. fB-cDNA transfections were performed 
using Lipofectine (Invitrogen) as recommended by the manufacturer. Cells were plated in p60 
plates 1 day prior to transfection at 5 x 105 cells per well. Transfections were carried out with 
10 μg of the pCI-Neo constructs and 24 μl of Lipofectine in a total volume of 1 ml of medium 
per well. Stable transfected CHO cells were cloned by limiting dilution and clones producing 
the highest levels of fB (fB-WT 20μg/ml; fB-D279G 2μg/ml) were expanded for production. 
fB concentration was quantified by ELISA as previously described (11). The recombinant fBs 
were purified from tissue culture supernatant by affinity chromatography using the JC1 
monoclonal antibody (anti-human Bb, a gift from Prof. B.P. Morgan, Cardiff, UK) coupled to 
a HiTrap NHS-activated column according to the manufacturer’s instructions (GE 
Healthcare).  Bound fB was eluted with 0.1M Glycine/HCl pH 2.5, immediately neutralized 
with 2M Tris pH 8.6 and re-purified by gel filtration on a SuperoseTM 6 10/300 column (GE 
Healthcare). Both fB-WT and fB-D279G were obtained without any detectable contaminants 
or aggregates (Supplementary Figure 1A). 
Generation and purification of C3bB complexes. 
The Ni2+ cation was used instead of Mg2+ to promote a stable C3bB(Ni2+) complex 
that is otherwise undistinguishable from the physiological C3bB(Mg2+) pro-convertase. 
Purified C3b and fB were mixed in an (1:2) molar excess of fB in 20mM Tris, pH=7.6 buffer 
containing 50mM NaCl and either 20 mM EDTA or in 5mM NiCl2 and allowed to interact for 
15 at room temperature. Subsequently, both preparations were size-fractionated by gel 
filtration chromatography on a calibrated SuperoseTM 6 10/300 column (GE Healthcare) 
(Supplementary Figure 1B). In the absence of divalent cations (EDTA-sample), fB does not 
interact with C3b and both proteins elute separately from the Superose column as illustrated 
by the SDS-PAGE analysis of the corresponding fractions (Supplementary Figure 1C). In the 
presence of Ni2+ and a 1:2 molar excess of fB, C3b readily interacts with fB to form 
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C3bB(Ni2+) complexes. SDS-PAGE characterization of the elution fractions from the 
Superose column illustrates the presence of the C3bB(Ni2+) complex which elutes from the 
column in a single peak that precedes and partially overlaps the peak containing the single 
C3b molecules (Supplementary Figures 1B and 1C). To avoid a potential contamination of 
single C3b molecules in the fractions corresponding to the C3bB(Ni2+) complex, samples for 
the EM analysis were collected exclusively from the initial elution fractions of the peak 
containing the C3bB(Ni2+) complex. 
Generation and purification of C3bBb complexes.  
 We have used the fB-D279G mutant instead of the fB-WT protein to promote a 
relatively stable active C3bBb convertase. For the generation of the C3bB complex, purified 
C3b and fB-D279G were mixed in an (1:2) molar excess of fB in 20mM Tris, pH=7.6 buffer 
containing 50mM NaCl and 5mM MgCl2 and were incubated for 15 minutes at room 
temperature. Subsequently, we added fD (Comptech. Inc., Tyler, USA) at a 1:500 molar ratio 
to fB, incubated for 1 minute at 37ºC and size-fractionated the mix by gel filtration 
chromatography on a calibrated SuperoseTM 6 10/300 column (GE Healthcare) 
(Supplementary Figure 4A). The presence of C3bBb complexes was demonstrated by SDS-
PAGE analysis illustrating that, as expected, most of the Bb fragment eluted in the fractions 
containing the C3b molecule (Supplementary Figure 4B). The C3bBb complex eluted from 
the column in a single peak that significantly overlapped the peak containing the single C3b 
molecules (Supplementary Figures 4A and 4B). To minimize the contamination of single C3b 
molecules in the fractions corresponding to the C3bBb complex, samples for the EM analysis 
were collected exclusively from the initial elution fractions of the peak containing the C3bBb 
complex. 
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Legends to Supplementary Figures 
Figure S1. Purification of C3b, fB and the C3bB(Ni2+) complex. 
(A) Purification of C3b and fB. Chromatograms from the final step of C3b and fB-WT 
purification on a Superose 6 10/300 gel filtration column. The Y-axis (milliabsorbance units, 
mAU) plots absorbance at 280 nm, the X-axis plots retention time in ml. Vertical lines 
indicate the fractions that were pooled for generating the C3bB(Ni2+) complex and for the EM 
experiments. The Coomassie stained gel illustrates purity of the final C3b and fB 
preparations. 
(B) Purification of the C3bB(Ni2+) complexes. Elution profiles of the C3b-fB mix in the 
presence of 20mM EDTA (No complex formed; dotted line) or 5mM NiCl2 (Complex 
formed; solid line) from the Superose 6 10/300 gel filtration column. The Y-axis 
(milliabsorbance units, mAU) plots absorbance at 280 nm, the X-axis plots number of fraction 
collected. Elution position for fB, C3b and the C3bB(Ni2+) complex are indicated. 
(C) Characterization of C3bB(Ni2+) and complexes by SDS-PAGE. Fractions of the gel 
filtration chromatography experiments shown in (b) were analyzed by SDS-PAGE silver 
stained gels. The presence of the C3bB(Ni2+) complex was clearly demonstrated in the 
presence of 5mM NiCl2, as illustrated by the advanced elution position of fB (fractions 40-
43), compared to that of the single fB molecules (fractions 45-48). Note that for the EM 
analysis of the C3bB(Ni2+) complex only fractions 40 and 41 were used. 
 
Figure S2. Electron micrographs of C3b and C3bB(Ni2+) 
Selected field of an electron micrograph of C3b (a) and C3bB(Ni2+) complex (b). 
Scale bar represents 100nm. Some representative images of individual molecules are 
indicated using arrows. 
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Figure S3. Image processing of C3bB(Ni2+) using angular refinement methods  
Angular refinement was performed in two independent experiments from two different 
volumes, either a low-pass filtered version of the atomic structure of C3b (a) or a random 
noisy Gaussian blob (b). Three views of the initial template in each case and of several output 
volumes along the progression of the refinement are shown. It can be noted that two very 
distantly related initial references converge into a similar 3D structure, indicating the absence 
of bias of the initial template during the refinement and the accuracy of the final 
reconstruction. 
 
Figure S4. Output solutions after fitting the atomic structure of the vWA and the SP 
domains of fB (amino acids 253 to 764) into the EM density for fB extracted from the 3D 
structure of C3bB(Ni2+). 
(A) List of the top 11 solutions automatically obtained in the fitting experiment using 
computational methods with their corresponding cross-correlation values for the comparison 
between the EM density and the atomic structures. The table includes an indication of 
whether the vWA-SP orientation was interpreted as compatible with the continuity of the 
polypeptide chain (labeled “OK”) or incompatible with this continuity (labeled “flip”). The 
figure also shows the correlation values for the first two fitting outputs (20 and 21) that are 
significantly different from the top 11 outputs. 
(B) All the output solutions considered to be correct of the above list are practically identical 
and represented just slightly variations around a similar common output. These solutions are 
depicted as ribbons using a different color for each solution. 
(C) Similarly, all “flipped” solutions were very similar and they are also represented as 
ribbons using different colors. 
(D) The two outputs with low cross-correlation values are also color-coded. 
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Figure S5. Purification of the C3bBb complex. 
(A) Purification of the C3bBb complexes. Elution profiles of the C3b / fB-D279G mix in the presence 
of 5mM MgCl2 and fD (active convertase formed; solid line) and isolated C3b (dotted line) from the 
Superose 6 10/300 gel filtration column. The Y-axis (milliabsorbance units, mAU) plots absorbance at 
280 nm, the X-axis plots number of fraction collected. Elution position for the Bb fragment, C3b and 
the C3bBb complex are indicated.  
(B) Characterization of C3bBb complexes by SDS-PAGE. Fractions of the gel filtration 
chromatography experiments shown in (a) were analyzed by SDS-PAGE silver stained gels. The 
presence of the C3bBb complex was clearly demonstrated by the earlier elution of the Bb fragment 
(fractions 37-41), compared to that of the single Bb molecules (fractions 47-50). Only the initial 
fractions (38 and 39) of the C3bBb peak from gel filtration chromatography were used in the EM 
experiments to minimize the presence of single C3b molecules in the C3bBb preparations. 
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